Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite ...

Leerink Partners trimmed its Q2 2025 earnings estimate for Eli Lilly to $5.40 per share, down from $5.54. Several firms ...

This week, Phil Oakley has analysed two shares, DexCom (US:DXCM) and Auto Trader (AUTO), which have decent earnings growth forecasts but rich valuations. It looks like both companies will need ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...